Literature DB >> 7961102

K-ras and p53 alterations in genomic DNA and transcripts of human pancreatic adenocarcinoma cell lines.

H Suwa1, T Yoshimura, N Yamaguchi, K Kanehira, T Manabe, M Imamura, H Hiai, M Fukumoto.   

Abstract

We analyzed 15 human pancreatic adenocarcinoma cell lines for alterations of the K-ras and the p53 genes and their transcripts. In 11 cell lines (73.3%), point mutations of the K-ras gene were found at codon 12 in exon 1. In 9 cell lines one allele was mutated and the other was wild type, and both the alleles were expressed into mRNA. In one cell line both alleles of codon 12 were mutated to TGT and GTT, respectively, but only TGT was transcribed into mRNA. Alterations in mRNA of the p53 gene were detected in 10 cell lines (66.7%). Analysis of the genomic sequence of the p53 gene revealed that the alterations consisted of 6 cases of base pair substitutions and 1 case of 1-bp deletion in evolutionarily conserved exons 5 to 8, 2 cases of splicing mutations in exon 4, and 1 case of novel deletion from exons 2 to 9. In 14 cell lines (93.3%), alterations were identified in the K-ras or p53 gene. Of these, 4 cell lines harbored K-ras mutations without p53 alteration, whereas 3 cell lines exhibited p53 alterations without K-ras mutation. Thus, it is suggested that activation of the K-ras gene and inactivation of the p53 gene are strongly and cooperatively associated with pancreatic carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7961102      PMCID: PMC5919355          DOI: 10.1111/j.1349-7006.1994.tb02898.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


polymerase chain reaction reverse transcription‐PCR single strand conformation polymorphism
  41 in total

1.  K-ras mutation is an early event in pancreatic duct carcinogenesis in the Syrian golden hamster.

Authors:  W L Cerny; K A Mangold; D G Scarpelli
Journal:  Cancer Res       Date:  1992-08-15       Impact factor: 12.701

Review 2.  Pancreatic carcinoma.

Authors:  A L Warshaw; C Fernández-del Castillo
Journal:  N Engl J Med       Date:  1992-02-13       Impact factor: 91.245

3.  S26 ribosomal protein RNA: an invariant control for gene regulation experiments in eucaryotic cells and tissues.

Authors:  S Vincent; L Marty; P Fort
Journal:  Nucleic Acids Res       Date:  1993-03-25       Impact factor: 16.971

Review 4.  The p53 tumour suppressor gene.

Authors:  A J Levine; J Momand; C A Finlay
Journal:  Nature       Date:  1991-06-06       Impact factor: 49.962

5.  Splicing mutations of the p53 gene in human hepatocellular carcinoma.

Authors:  M Y Lai; H C Chang; H P Li; C K Ku; P J Chen; J C Sheu; G T Huang; P H Lee; D S Chen
Journal:  Cancer Res       Date:  1993-04-01       Impact factor: 12.701

6.  Association of Ki-ras with amplified DNA sequences, detected in human ovarian carcinomas by a modified in-gel renaturation assay.

Authors:  M Fukumoto; R D Estensen; L Sha; G J Oakley; L B Twiggs; L L Adcock; L F Carson; I B Roninson
Journal:  Cancer Res       Date:  1989-04-01       Impact factor: 12.701

7.  p53 gene mutations and protein accumulation in human ovarian cancer.

Authors:  J Kupryjańczyk; A D Thor; R Beauchamp; V Merritt; S M Edgerton; D A Bell; D W Yandell
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-01       Impact factor: 11.205

8.  Increased expression of mutant forms of p53 oncogene in primary lung cancer.

Authors:  R Iggo; K Gatter; J Bartek; D Lane; A L Harris
Journal:  Lancet       Date:  1990-03-24       Impact factor: 79.321

9.  Frequent glycine-to-aspartic acid mutations at codon 12 of c-Ki-ras gene in human pancreatic cancer in Japanese.

Authors:  Y Nagata; M Abe; K Motoshima; E Nakayama; H Shiku
Journal:  Jpn J Cancer Res       Date:  1990-02

10.  A novel combination of K-ras and myc amplification accompanied by point mutational activation of K-ras in a human lung cancer.

Authors:  Y Taya; K Hosogai; S Hirohashi; Y Shimosato; R Tsuchiya; N Tsuchida; M Fushimi; T Sekiya; S Nishimura
Journal:  EMBO J       Date:  1984-12-01       Impact factor: 11.598

View more
  10 in total

1.  Clinical significance of serum p53 antigen in patients with pancreatic carcinomas.

Authors:  H Suwa; G Ohshio; N Okada; Z Wang; M Fukumoto; T Imamura; M Imamura
Journal:  Gut       Date:  1997-05       Impact factor: 23.059

2.  In vitro models of pancreatic cancer for translational oncology research.

Authors:  Georg Feldmann; Sherri Rauenzahn; Anirban Maitra
Journal:  Expert Opin Drug Discov       Date:  2009-04-01       Impact factor: 6.098

3.  Detection of extrapancreatic nerve plexus invasion of pancreatic adenocarcinoma. Cytokeratin 19 staining and K-ras mutation.

Authors:  H Suwa; R Hosotani; M Kogire; R Doi; G Ohshio; M Fukumoto; M Imamura
Journal:  Int J Pancreatol       Date:  1999-12

4.  Alterations in the tumor suppressor genes p53, RB, p16/MTS1, and p15/MTS2 in human pancreatic cancer and hepatoma cell lines.

Authors:  M Kaino
Journal:  J Gastroenterol       Date:  1997-02       Impact factor: 7.527

5.  Evidence for activation of mutated p53 by apigenin in human pancreatic cancer.

Authors:  Jonathan C King; Qing-Yi Lu; Gang Li; Aune Moro; Hiroki Takahashi; Monica Chen; Vay Liang W Go; Howard A Reber; Guido Eibl; O Joe Hines
Journal:  Biochim Biophys Acta       Date:  2011-12-29

Review 6.  Analysis of TP53 mutation status in human cancer cell lines: a reassessment.

Authors:  Bernard Leroy; Luc Girard; Antoinette Hollestelle; John D Minna; Adi F Gazdar; Thierry Soussi
Journal:  Hum Mutat       Date:  2014-05-06       Impact factor: 4.878

7.  Overexpression of the rhoC gene correlates with progression of ductal adenocarcinoma of the pancreas.

Authors:  H Suwa; G Ohshio; T Imamura; G Watanabe; S Arii; M Imamura; S Narumiya; H Hiai; M Fukumoto
Journal:  Br J Cancer       Date:  1998       Impact factor: 7.640

8.  p53 mutations in two patients with intraductal papillary adenoma of the pancreas.

Authors:  M Kaino; S Kondoh; S Okita; S Ryozawa; S Hatano; K Shiraishi; S Kaino; T Akiyama; K Okita; T Kawano
Journal:  Jpn J Cancer Res       Date:  1996-12

9.  Specific T-cell immunity against Ki-ras peptides in patients with pancreatic and colorectal cancers.

Authors:  Y Shono; H Tanimura; M Iwahashi; T Tsunoda; M Tani; H Tanaka; K Matsuda; H Yamaue
Journal:  Br J Cancer       Date:  2003-02-24       Impact factor: 7.640

10.  Low incidence of point mutations in H-, K- and N-ras oncogenes and p53 tumor suppressor gene in renal cell carcinoma and peritoneal mesothelioma of Wistar rats induced by ferric nitrilotriacetate.

Authors:  Y Nishiyama; H Suwa; K Okamoto; M Fukumoto; H Hiai; S Toyokuni
Journal:  Jpn J Cancer Res       Date:  1995-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.